What is HC Wainwright’s Forecast for DAWN Q1 Earnings?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Day One Biopharmaceuticals in a research report issued on Thursday, October 31st. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of ($0.34) for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.23) EPS and Q4 2025 earnings at ($0.20) EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same period in the prior year, the business earned ($0.54) earnings per share.

Other equities research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. lowered their price target on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and increased their price target for the stock from $11.00 to $24.00 in a research note on Thursday, August 1st. Wedbush restated an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Needham & Company LLC reiterated a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.71.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock opened at $14.65 on Monday. Day One Biopharmaceuticals has a 52 week low of $10.90 and a 52 week high of $18.07. The firm’s 50-day simple moving average is $14.19 and its two-hundred day simple moving average is $14.39. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of -14.22 and a beta of -1.51.

Insider Buying and Selling

In other news, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the completion of the transaction, the insider now directly owns 1,097,535 shares in the company, valued at $15,606,947.70. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total transaction of $426,600.00. Following the completion of the sale, the insider now owns 1,097,535 shares in the company, valued at approximately $15,606,947.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Samuel C. Blackman sold 2,232 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $31,248.00. Following the transaction, the insider now directly owns 1,127,535 shares of the company’s stock, valued at $15,785,490. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,748 shares of company stock valued at $689,072. Company insiders own 8.40% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. increased its stake in Day One Biopharmaceuticals by 38.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after acquiring an additional 1,002 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Day One Biopharmaceuticals in the 2nd quarter worth about $113,000. Point72 DIFC Ltd bought a new position in shares of Day One Biopharmaceuticals during the 2nd quarter valued at about $124,000. Hsbc Holdings PLC purchased a new position in shares of Day One Biopharmaceuticals during the 2nd quarter valued at about $163,000. Finally, Bayesian Capital Management LP bought a new stake in Day One Biopharmaceuticals in the 1st quarter worth approximately $221,000. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.